2018 Board Review Pre-Test:
MCS II: Durable MCS Selection and Outcomes

MCS II: Durable MCS Selection and Outcomes - Nir Uriel, MD

Please complete this brief Pre-Test to give a baseline for learning .

Question Title

* 1. Which of the following is true about continuous flow LVADs?

A. They have been demonstrated to be superior to optimal medical therapy as a bridge-to-transplant in a randomized controlled trial

B. The reduced pulsatility has been demonstrated to adversely impact renal function over time

C. Patient-reported quality of life improves within 3 months of device implantation and remains stable throughout at least 2 years

D. Compared to pulsatile LVADs in the DT application, continuous flow VAD patients had better functional capacity and quality of life

Question Title

* 2. Please provide your first and last name.
Pre-test questions will not be scored, your name is required solely to confirm completion.

First Name *

Last Name